From: Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women
 | Black | White | Overall | |
---|---|---|---|---|
Overall | N | 550 (79.9%) | 138 (20.1%) | 688 (100%) |
Age at diagnosis | Median/IQR | 55.0/(46, 62) | 52.5/(45, 60) | 54.5/(46, 61) |
Subtype | Luminal A | 322 (59.3%) | 91 (65.9%) | 413 (60.6%) |
HER2-positive | 80 (14.7%) | 28 (20.3%) | 108 (15.9%) | |
Triple-negative | 141 (26.0%) | 19 (13.8%) | 160 (23.5%) | |
ER | Positive | 366 (66.7%) | 107 (77.5%) | 473 (68.9%) |
Negative | 183 (33.3%) | 31 (22.5%) | 214 (31.1%) | |
PR | Positive | 284 (52.1%) | 82 (59.4%) | 366 (53.6%) |
Negative | 261 (47.9%) | 56 (40.6%) | 317 (46.4%) | |
HER2 | Positive | 80 (14.7%) | 28 (20.3%) | 108 (15.8%) |
Negative | 464 (85.3%) | 110 (79.7%) | 574 (84.2%) | |
Stage | I | 221 (40.2%) | 62 (45.3%) | 283 (41.2%) |
II | 250 (45.5%) | 57 (41.6%) | 307 (44.7%) | |
III/IV | 79 (14.4%) | 18 (13.1%) | 97 (14.1%) | |
Grade | Low | 69 (12.6%) | 29 (21.5%) | 98 (14.4%) |
Intermediate | 186 (34.1%) | 60 (44.4%) | 246 (36.1%) | |
High | 291 (53.3%) | 46 (34.1%) | 337 (49.5%) | |
Tumor size | < 1.0 | 54 (9.9%) | 21 (15.3%) | 75 (11.0%) |
1–1.9 | 199 (36.4%) | 54 (39.4%) | 253 (37.0%) | |
≥ 2.0 | 294 (53.7%) | 62 (45.3%) | 356 (52.0%) | |
LN status | Positive | 221 (41.2%) | 51 (37.5%) | 272 (40.4%) |
Negative | 316 (58.8%) | 85 (62.5%) | 401 (59.6%) | |
OS | 10-year rate | 0.78 | 0.87 | 0.81 |
95% CI | 0.72–0.84 | 0.79–0.92 | 0.76–0.85 | |
DSS | 10-year rate | 0.84 | 0.92 | 0.87 |
95% CI | 0.78–0.89 | 0.84–0.96 | 0.82–0.90 |